AC
RCKT icon

Apogem Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Apogem Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,056
Closed -$224K – 100
2022
Q3 		$224K Sell
14,056
-6,613
-32% -$103K 0.22% 114
2022
Q2 		$284K Buy
20,669
+5,456
+36% +$65K 0.26% 117
2022
Q1 		$241K Buy
15,213
+5,547
+57% +$95.8K 0.16% 142
2021
Q4 		$211K Buy
+9,666
New +$264K 0.14% 158

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Apogem Capital's RCKT Position: Q4 2022 in Review

Apogem Capital sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 14,056 shares — an estimated $224K sold.

Apogem Capital first reported a position in RCKT in Q4 2021 and held it in 4 quarters. The position peaked at $284K in Q2 2022. 168 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

  • Apogem Capital reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 14,056 Rocket Pharmaceuticals shares in Q4 2022, an estimated $224K.
  • Apogem Capital first reported a position in Rocket Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Apogem Capital's Rocket Pharmaceuticals position peaked at $284K in Q2 2022.
  • 168 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.